Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine in Neonates With Hypoxic-Ischemic Encephalopathy
NCT03913221Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of caffeine in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Area Under Plasma Concentration-time at Time t. Started Aug 2019; status: completed.
02
Drugs
caffeine
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT03913221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913221.